Understanding SCN2A Brain MRI Findings Across Phenotypes

Pathogenic variants in the SCN2A gene cause a broad spectrum of neurological conditions. These disorders range from self-limited familial neonatal-infantile epilepsy to refractory developmental and epileptic encephalopathies. Consequently, clinicians frequently encounter diagnostic uncertainty when evaluating these young infants. A systematic evaluation of SCN2A brain MRI findings provides vital clarity regarding neurodevelopmental trajectories and disease severity. Recently, an international collaborative multicenter cohort study comprehensively delineated these imaging characteristics across 354 individuals. The researchers analyzed participants from the Bonn and Melbourne Natural History Study alongside a published literature cohort. Blinded pediatric neuroradiologists reviewed scans to classify structural abnormalities according to standardized criteria. Interestingly, abnormal neuroimaging features appeared in 41% of the prospective cohort and 45% of published patients. These observations show that while many children show normal initial scans, a substantial subset develops distinct structural alterations. Therefore, early neuroimaging interpretation requires careful contextualization within the patient's specific clinical phenotype. Clinicians must recognize that normal baseline imaging does not exclude aggressive genetic epilepsy. Instead, systematic neuroradiological surveillance helps clinicians track neurodegenerative changes and tailor therapeutic strategies effectively. Furthermore, timely neuroimaging facilitates early discussions regarding prognosis and multidisciplinary management.

Spectrum of Structural Brain Anomalies and White Matter Changes

The multicenter investigation documented a characteristic spectrum of cranial structural pathology across the entire cohort. Overall, white matter changes emerged as the most frequent imaging abnormality, affecting 17% of individuals. In addition, diffuse supratentorial cerebral atrophy occurred in approximately 15% of evaluated patients. Thinning of the corpus callosum represented another common finding, which pediatric radiologists detected in 10% of cases. However, white matter changes demonstrated notable variability over time. In many affected infants, these white matter signal alterations were transient and non-specific. For example, myelination delay frequently improved on subsequent follow-up scans as the child matured. Furthermore, clinicians often observed patchy T2-hyperintensities that did not correspond directly to focal neurological deficits. Because these white matter findings fluctuate, clinicians should interpret isolated signal anomalies cautiously. They must avoid misinterpreting delayed myelination as irreversible parenchymal damage. Nevertheless, persistent or progressive white matter loss strongly correlates with adverse developmental outcomes. Thus, serial magnetic resonance imaging remains invaluable for identifying sustained cerebral involvement. By comparing successive neuroimaging scans, pediatric neurologists can distinguish harmless developmental delays from progressive encephalopathic injury. Moreover, differentiating transient myelination lag from true dysmyelination guides appropriate metabolic and genetic testing.

Evolution of Cerebral Atrophy and Timing of Scans

One of the most clinically meaningful revelations concerns the temporal evolution of cerebral atrophy. Specifically, volumetric brain loss rarely appeared on neuroimaging performed during the initial presentation of seizures. Instead, supratentorial atrophy developed almost exclusively on magnetic resonance scans obtained four weeks or later following epilepsy onset. Moreover, this progressive atrophy concentrated within two distinct clinical subgroups: early-onset severe encephalopathy and later-onset infantile epilepsy. In contrast, children presenting with self-limited familial neonatal-infantile epilepsy maintained normal brain parenchymal volumes throughout their clinical course. These temporal patterns indicate that neurodegeneration reflects secondary epileptic encephalopathic injury rather than primary congenital maldevelopment. Therefore, unrelenting seizure activity and associated excitotoxicity likely drive progressive parenchymal loss in susceptible patients. Furthermore, early therapeutic cessation of seizures may protect vulnerable cortical and subcortical structures. When clinicians achieve prompt seizure control, they potentially halt this secondary cerebral degeneration. Consequently, clinicians must schedule repeat imaging at strategic intervals rather than relying entirely on initial neonatal scans. Documenting volumetric changes over time provides critical objective evidence regarding treatment efficacy and long-term neurodevelopmental prognosis. Additionally, repeating neuroimaging helps clinicians identify subtle structural loss that correlates with developmental regression.

Hippocampal Alterations, Cortical Malformations, and Cerebellar Atrophy

Beyond generalized atrophy, detailed radiologic review uncovered discrete regional anomalies and developmental malformations in select patients. Notably, cortical malformations occurred in approximately 5% of the total study cohort. Polymicrogyria represented the predominant malformation of cortical development identified by neuroradiologists. Additionally, hippocampal abnormalities emerged as an underrecognized yet critical neuroimaging feature. In the novel cohort, 15% of children displayed distinct hippocampal alterations, including volume loss and signal hyperintensity. In comparison, previously published literature reported hippocampal involvement in only 2% of patients. This striking difference highlights the superior detection capability of dedicated pediatric neuroimaging protocols. Because older retrospective reports often lacked high-resolution sequences, earlier studies underestimated mesial temporal involvement. Furthermore, distinctive structural patterns occurred in non-epileptic phenotypes such as episodic ataxia. Among patients presenting with episodic ataxia, isolated cerebellar atrophy appeared in 17% of evaluated cases. Meanwhile, these ataxia patients typically maintained normal supratentorial architecture. Therefore, localized cerebellar vulnerability indicates that ion channel dysfunction can trigger regional neurodegeneration independently of epileptic seizures. Consequently, radiologists must scrutinize both temporal and infratentorial structures during diagnostic evaluations. Ultimately, precise anatomical localization enhances phenotypic stratification and deepens biological understanding.

Clinical Implications for Pediatric Practice and Biomarker Discovery

These comprehensive neuroradiological insights carry significant implications for bedside practice and therapeutic development. First, baseline imaging frequently appears normal in neonates experiencing severe epileptic encephalopathy. Consequently, pediatricians must not offer false reassurance based solely on an unremarkable initial scan. Instead, clinicians must counsel families that structural changes, such as cerebral atrophy, may evolve over subsequent months. Second, the correlation between persistent seizures and delayed atrophy reinforces the urgent need for rapid seizure control. Sodium channel blockers frequently deliver superior anticonvulsant efficacy in gain-of-function phenotypes. Therefore, early molecular diagnosis allows physicians to initiate targeted channel-blocking therapies before irreversible parenchymal loss occurs. In addition, quantitative magnetic resonance imaging metrics offer promising surrogate endpoints for upcoming gene-targeted clinical trials. Because structural loss progresses predictably in severe subgroups, standardized neuroimaging protocols can objectively gauge neuroprotective therapeutic benefits. Nevertheless, clinicians should recognize study limitations, including retrospective designs and heterogeneous imaging protocols across global centers. By harmonizing prospective neuroimaging standards, international consortia will strengthen biomarker discovery and improve personalized care for vulnerable pediatric patients. Ultimately, systematic radiological surveillance ensures timely interventions that optimize neurodevelopmental outcomes for affected children.

Frequently Asked Questions

How common are structural brain abnormalities on MRI in patients with SCN2A-related disorders?

Approximately 41% to 45% of individuals with SCN2A disease show brain MRI abnormalities. The most frequent findings include supratentorial cerebral atrophy, transient white matter hyperintensities, and corpus callosum thinning. Notably, neonates frequently present with normal baseline imaging, with structural abnormalities often emerging several weeks after seizure onset.

Why does cerebral atrophy typically appear weeks after seizure onset rather than at birth?

Atrophy reflects progressive secondary neurodegeneration driven by prolonged epileptic activity and excitotoxic cellular stress rather than congenital brain maldevelopment. Initial neonatal neuroimaging is frequently normal. Significant supratentorial atrophy primarily develops four weeks or later following seizure onset, particularly in severe early-onset epileptic encephalopathy phenotypes.

What is the clinical significance of hippocampal alterations and cortical malformations in SCN2A disease?

Cortical malformations, particularly polymicrogyria, occur in roughly 5% of patients, pointing to early developmental disruption. Hippocampal alterations, including volume loss and signal changes, affect up to 15% of individuals. Recognizing these structural lesions guides precision antiseizure therapy, informs long-term cognitive prognostication, and assists in future trial stratification.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Bamborschke D et al. [object Object] Neurology. 2026 Oct 13. doi: 10.1212/WNL.0000000000218541. PMID: 42758957.


2. Wolff M, Johannesen KM, Hedrich UB, et al. Genetic and phenotypic heterogeneity in SCN2A deficiency. Brain. 2017;140(5):1316-1336.


3. Sanders SJ, Campbell AJ, Cottrell JR, et al. Progress in Understanding and Treating SCN2A-Mediated Disorders. Trends Neurosci. 2018;41(7):442-456.